Association Between Glutathione S-Transferase Omega 1 A140D Polymorphism in the Turkish Population and Susceptibility to Non-Small Cell Lung Cancer

Abstract

Recent years have seen a growing evidence of ethnic differences in the frequency of glutathione S-transferase omega 1 (GSTO1) A140D gene polymorphism, which is associated with various cancers such as breast and liver. Until now however, no association has been investigated between the GSTO1 A140D polymorphism and lung cancer. The aim of our study was to see if there was one in the Turkish population. To do that, we identifi ed GSTO1 A140D polymorphism in 214 unrelated healthy individuals and 172 patients with non-small cell lung cancer (NSCLC) using the polymerase chain reaction -restriction fragment length polymorphism (PCR-RFLP) method. The frequencies of A/A (wild type), A/D (heterozygous mutant), and D/D (homozygous mutant) GSTO1 A140D genotypes in healthy subjects were 48 %, 41 %, and 11 %, respectively. In NSCLC patients they were 48 %, 45 %, and 7 %, respectively. We found no signifi cant association between the GSTO1 A140D gene polymorphism and NSCLC or its histological subtypes, namely squamous cell carcinoma or adenocarcinoma. Furthermore, this polymorphism did not correlate with smoking. Our study is the fi rst to show that the frequency of GSTO1 A140D gene polymorphism in the Turkish population is similar to other Caucasian populations and that this polymorphism is not associated with susceptibility to NSCLC.

Genetic polymorphisms in Glutathione S-transferase Omega (GSTO) and cancer risk: a meta-analysis of 20 studies

“…In total, 20 articles 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 were identified according to the inclusion and exclusion criteria. The flow chart of literature search and study selection was illuminated in Figure 1 .…”

“…Among the 20 articles, 5 of them were studies of Caucasian 9 12 15 19 27 , 10 studies were of Asian 10 11 17 18 20 24 25 26 28 29 and the rest were study of different races (white and non-white groups) 13 16 21 22 23 . Cancer cases were all diagnosed histologically or pathologically in these studies.…”

“…But the results were inconsistent. Several investigators have reported an increased risk of breast cancer, hepatocellular carcinoma, bile duct carcinoma, urothelial cancer, acute lymphoblastic leukemia and non-small cell lung cancer for the GSTO1 A140D 9 10 11 12 . However, Granja et al 13 and Marahatta et al 14 did not find any significant association in thyroid and colorectal cancers.…”

Xenobiotic/drug metabolizing enzyme and TP53 polymorphisms and clinical outcome in advanced nonsmall cell lung cancer patients

“…The protective role against cell toxicity can be weakened if the enzyme activity is reduced, but the findings related to the GSTO1 gene polymorphism Ala140Asp (A140D) are still inconclusive (19,20). Recent studies have established an association between the GSTO1 (A140D) gene polymorphism and increased risk of several carcinomas such as breast and hepatocellular carcinoma (21) but not with lung or colorectal cancers (21,22).…”

Significance of Polymorphisms and Expression of Enzyme-Encoding Genes Related to Glutathione in Hematopoietic Cancers and Solid Tumors

“…Three polymorphisms within the GSTO class of enzymes were described, GSTO1 ∗ A140D, GSTO1 ∗ E155del, and GSTO2 ∗ N142D [ 49 ]. Research results indicate that there is a relationship between the GSTO1 ∗ A140D polymorphism and an increased risk of breast cancer, hepatocellular carcinoma, cholangiocarcinoma, urothelial cancer, acute lymphoblastic leukemia, and non-small-cell lung cancer [ 50 ]. No known relationship was confirmed between polymorphisms of the GSTO1 and GSTO2 genes and an increased risk of development of breast, thyroid, and colon cancer [ 51 ].…”